ABSI at a glance
Absci Corp (ABSI, SEC CIK 1672688) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Absci Corp (ABSI) shares worth $791.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Szela Mary T on June 30, 2026 of 12,900 shares at $11.54 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.8M
- −38.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $791.6M · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 designation was preliminarily enjoined in August 2026
- Regulatory risk: CMS finalized GLOBE Model for 2027, potentially reducing partner revenue, milestones and royalties
- Clinical risk: ABS-201 Phase 1/2a trial continues dosing MAD cohorts in Australia
- Financial risk: $173.7 million cash, equivalents and marketable securities expected to fund at least 12 months
- Operating risk: No partner has licensed related intellectual property for clinical or commercial use as of November 12, 2026
Management Discussion & Analysis
- Revenue $0.3M, down 20% YoY from $0.4M, reflecting milestone timing and program mix
- Operating loss $35.0M vs $30.2M YoY, with R&D expense $23.6M, up 22%
- Lead program ABS-201: positive interim safety data, half-life at least 65 days
- Cash, equivalents and marketable securities $173.7M; operating cash used $83.3M through nine months
- June offering generated $93.6M; management expects liquidity sufficient for at least 12 months
AI summary of the ABSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter fiscal 2026 results announced for period ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item 8.01: Other Events
- Absci released an investor presentation on November 12, 2026 covering internal pipeline program updates
- Pipeline disclosures may affect investor views on development priorities, clinical progress and future catalysts
Item EX-99.2: Item EX-99.2
- Corporate presentation highlights ABS-201’s Ph1/2a PHL program, with interim proof-of-concept readout expected December 2026
- Interim SAD data showed favorable blinded safety and tolerability, with half-life of at least 65 days
Item EX-99.1: Item EX-99.1
- ABS-201 HEADLINE trial on track, with 13-week pattern hair-loss proof-of-concept data expected December 2026 and full 26-week data early 2027
- Planned Phase 2 STORYLINE endometriosis trial targets approximately 150 patients across approximately 10 countries, with initiation anticipated mid-2027
Item 8.01: Other Events
- Absci released an August 11, 2026 investor presentation with internal pipeline program updates
- Presentation provides investors current visibility into drug-development priorities and pipeline progress
Item EX-99.1: Item EX-99.1
- Positive interim Phase 1 ABS-201 data: favorable safety profile and estimated half-life of at least 65 days
- Pattern hair-loss interim proof-of-concept data expected second half 2026, with full readout targeted for early 2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced on August 11, 2026
- Press release containing financial results furnished as Exhibit 99.1, the key source for investor review
Item 8.01: Other Events
- Interim Phase 1 data released for ABS-201 in the HEADLINE™ trial
- Clinical update creates a potential valuation catalyst for Absci’s drug-development pipeline
Item EX-99.1: Item EX-99.1
- Positive Phase 1 safety signal: 32 participants across 150–1800 mg SAD cohorts, with no serious adverse events
- ABS-201 half-life estimated at least 65 days, supporting potential two- or three-dose administration over six months
AI summaries of ABSI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABSI
Don't miss the next ABSI filing
- Alerts as it files. A push when ABSI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABSI, by share count.
- Ask anything. An AI agent that reads every ABSI filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McClain Sean | F | Oct 29, 2026 | 79,860 | $12.10 |
| McClain Sean | F | Oct 12, 2026 | 23,293 | $10.16 |
| Bedrick Todd | F | Oct 12, 2026 | 22,325 | $10.16 |
| Jonasson Zachariah | F | Oct 12, 2026 | 387 | $10.16 |
| Jonasson Zachariah | F | Aug 31, 2026 | 8,320 | $8.71 |
| Somaratne Ransi Mudalinayake | A | Aug 3, 2026 | 383,000 | - |
| Szela Mary T | Buy | Jun 30, 2026 | 12,900 | $11.54 |
| McClain Sean | F | Jun 24, 2026 | 59,896 | $10.07 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.5M | $2.8M |
| Operating Income | - | -$108.9M | -$120.3M |
| Net Income | -$110.6M | -$103.1M | -$115.2M |
| Op. Margin | - | -2401.6% | -4297.0% |
| Net Margin | - | -2274.1% | -4113.7% |
| Balance Sheet | |||
| Total Assets | $217.3M | $213.6M | $216.3M |
| Equity | - | $179.1M | $189.4M |
| ROE | - | -57.6% | -60.8% |
| Per Share | |||
| EPS | $-1.20 | $-0.94 | $-0.84 |
| Cash Flow | |||
| Operating CF | - | -$72.4M | -$92.9M |
| CapEx | $860K | $404K | $1.1M |
Source: XBRL data in Absci Corp (ABSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ABSI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $791.6M |
| Q2 2026 | 29 | $1.15B |
| Q1 2026 | 30 | $241.4M |
| Q4 2025 | 25 | $281.0M |
| Q3 2025 | 26 | $190.8M |
| Q2 2025 | 25 | $143.4M |
| Q1 2025 | 23 | $117.1M |
| Q4 2024 | 19 | $93.5M |
- BlackRock+2.33M (+19%)
- Vanguard Capital Management LLC+919.8K (+15%)
- Bank of America Corp+706.4K (+125%)
- Vanguard Portfolio Management LLC+542.9K (+41%)
- Millennium Management+520.0K (+209%)
- Ameriprise Financial−4.45M (-64%)
- ARK Investment Management−996.4K (-8%)
- T. Rowe Price Group−868.9K (-58%)
- D.E. Shaw & Co−282.2K (-5%)
- Goldman Sachs Group−140.3K (-8%)
- Renaissance Technologies LLC+547.6K
- Principal Financial Group+15.8K
- Franklin Resources+15.7K
- FMR LLC (Fidelity)−25.41M
- Truist Financial−10.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 207 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABSI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- MEDP · Medpace Holdings IncServices-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
ABSI SEC filings: frequently asked questions
Which institutions hold ABSI stock?
As of September 30, 2026, the largest Absci Corp (ABSI) holders among the 13F filers tracked by SignalX were BlackRock ($156.2 million), ARK Investment Management ($128.5 million), State Street Corp ($91.1 million), Vanguard Capital Management LLC ($75.8 million), Advanced Micro Devices ($61.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABSI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84. The figures come from the XBRL data in the 10-K.
What did ABSI report in its latest 8-K?
Absci Corp (ABSI) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.
What are the latest ABSI SEC filings?
Absci Corp (ABSI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 30, 2026.
What is ABSI's SEC CIK number?
Absci Corp (ABSI)'s SEC Central Index Key (CIK) is 1672688. EDGAR lists every ABSI filing under that number.
Ask anything about ABSI
The research agent reads ABSI's filings, financials, insider trades and 13F holders, then answers with sources.